Boundless Bio, Inc. BOLD
Boundless Bio, Inc. (Nasdaq: BOLD) is an oncology drug developer. Its lead program, none active (BBI-940 clinical development halted Jun 2026), is in Pre-clinical.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| BBI-940 (KOMODO-1) | ER+/HER2- breast cancer post CDK4/6i; TNBC-LAR (discontinued June 2026 for low oral bioavailability) | small molecule | Phase 1 |
| BBI-355 (POTENTIATE, Phase 1/2) | oncogene-amplified cancers (enrollment ceased Jan 2026; trial wind-down ongoing) | small molecule | Phase 1 |
| BBI-825 (STARMAP) | oncogene-amplified cancers (wound down 2025) | small molecule | Phase 1 |
| Spyglass platform ecDTx discovery targets | — | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.